A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.

Abstract:

BACKGROUND:beta-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of beta-thalassemia and showed promise in clinical application. Using a human beta-globin transgenic mouse line in a beta-thalassemia diseased model generated with a lentiviral-mediated approach, we investigate the stable therapeutic effect on a common thalassemia syndrome. DESIGN AND METHODS:Human beta-globin gene lentiviral vector was constr ucted, followed by subzonal microinjection into single-cell embryos of beta(IVS-2-654)-thalassemia mice to generate a transgenic line. Human beta-globin gene expression was examined with RT-PCR, Western-blotting and ELISA. The hematologic parameters and tissue pathology were investigated over time in founder mice and their off-spring. RESULTS:Transgenic mice with stable expression of the lentivirus carrying human beta-globin gene were obtained. A marked improvement in red blood cell indices and a dramatic reduction in red blood cell anisocytosis, poikilocytosis and target cells were observed. Nucleated cell proportion was greatly decreased in bone marrow, and splenomegaly with extramedullary hematopoiesis was ameliorated. Iron deposition in liver was also reduced. There was a two-fold increase in the survival rate of the beta(IVS-2-654) mice carrying human beta-globin transgene. Significantly, the germline integration of the lentiviral construct was obtained and stable hematologic phenotype correction was observed over the next two generations of the transgenic mice. CONCLUSIONS:The generation of human beta-globin transgenic mice in a beta(IVS-2-654)-thalassemia mouse mediated with lentiviral vectors provides a useful model and offers an attractive means to investigate the transgenic stable therapeutic effect in beta-thalassemia.

journal_name

Haematologica

journal_title

Haematologica

authors

Li W,Xie S,Guo X,Gong X,Wang S,Lin D,Zhang J,Ren Z,Huang S,Zeng F,Zeng Y

doi

10.3324/haematol.12010

subject

Has Abstract

pub_date

2008-03-01 00:00:00

pages

356-62

issue

3

eissn

0390-6078

issn

1592-8721

pii

haematol.12010

journal_volume

93

pub_type

杂志文章
  • Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

    abstract::The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.144949

    authors: Castagnetti F,Breccia M,Gugliotta G,Martino B,D'Adda M,Stagno F,Carella AM,Avanzini P,Tiribelli M,Trabacchi E,Visani G,Gobbi M,Salvucci M,Levato L,Binotto G,Capalbo SF,Bochicchio MT,Soverini S,Cavo M,Martinelli G,

    更新日期:2016-10-01 00:00:00

  • Genetic modifiers of beta-thalassemia.

    abstract::As the defective genes for more and more genetic disorders become unravelled, it is clear that patients with apparently identical genotypes can have many different clinical conditions even in simple monogenic disorders. Beta thalassemia occurs when there is a deficiency in the synthesis of beta globin chains. The clin...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Thein SL

    更新日期:2005-05-01 00:00:00

  • Combined modality therapy in advanced Hodgkin's disease: a report on 218 patients with a median follow-up of eight years.

    abstract:BACKGROUND AND OBJECTIVE:This study was designed to evaluate the efficacy and toxicity of monthly alternating ABVD/MOPP compared to ABVD/OPP regimens in patients with advanced stage Hodgkin's disease (HD), as well as in early stage patients with systemic symptoms and/or bulky disease. DESIGN AND METHODS:218 patients w...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Anselmo AP,Cavalieri E,Enrici RM,Donato V,Pescarmona E,Biagini C,Mandelli F

    更新日期:1998-07-01 00:00:00

  • Ceftriaxone and amikacin as single daily dose in the empiric therapy for febrile episodes in neutropenic patients.

    abstract::One hundred thirty-three febrile episodes in 115 neutropenic patients with hematologic malignancies were empirically treated with ceftriaxone and amikacin in a single daily dose. An indwelling central venous catheter (CVC) was present in 44 cases. Septicemia was documented in 18 (41%) patients with CVC (13 gram-positi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Martino P,Girmenia C,Raccah R,Micozzi A,Cimino G,Mandelli F

    更新日期:1990-01-01 00:00:00

  • Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.

    abstract:BACKGROUND:Antithymocyte globulin or human Jurkat T-cell-line-derived antilymphocyte globulin is used in allogeneic stem cell transplantation to induce in vivo T-cell depletion to facilitate engraftment and lower graft-versus-host disease. In vitro studies suggest that antithymocyte globulin, besides causing T-cell dep...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12665

    authors: Ayuk F,Perez-Simon JA,Shimoni A,Sureda A,Zabelina T,Schwerdtfeger R,Martino R,Sayer HG,Alegre A,Lahuerta JJ,Atanackovic D,Wolschke C,Nagler A,Zander AR,San Miguel JF,Kröger N

    更新日期:2008-09-01 00:00:00

  • Seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia.

    abstract::The aim of this study was to identify new pathogenic variations of the UGT1A1 gene in 11 patients diagnosed with neonatal unconjugated hyperbilirubinemia. We describe two cases in which clinically unapparent heterozygotic mutations in the UGT1A1 gene may become evident in combination with certain environmental conditi...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.10585

    authors: D'Apolito M,Marrone A,Servedio V,Vajro P,De Falco L,Iolascon A

    更新日期:2007-01-01 00:00:00

  • Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.

    abstract::Long non-coding ribonucleic acids (RNAs) are a novel class of RNA molecules, which are increasingly recognized as important molecular players in solid and hematologic malignancies. Herein we investigated whether long non-coding RNA expression is associated with clinical and molecular features, as well as outcome of yo...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2017.166215

    authors: Papaioannou D,Nicolet D,Volinia S,Mrózek K,Yan P,Bundschuh R,Carroll AJ,Kohlschmidt J,Blum W,Powell BL,Uy GL,Kolitz JE,Wang ES,Eisfeld AK,Orwick SJ,Lucas DM,Caligiuri MA,Stone RM,Byrd JC,Garzon R,Bloomfield CD

    更新日期:2017-08-01 00:00:00

  • Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

    abstract::Patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma often present with B-symptoms or hemophagocytosis and generate an anti-tumor immune response. Specific serum cytokine levels or profiles may reflect the tumor burden, non-specific immune stimulation by the tumor or differences in the stre...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2017.177972

    authors: Knörr F,Damm-Welk C,Ruf S,Singh VK,Zimmermann M,Reiter A,Woessmann W

    更新日期:2018-03-01 00:00:00

  • HTLV-I positive adult T-cell leukaemia-lymphoma: report of a typical case from Italy.

    abstract::A case of acute adult T-cell leukemia-lymphoma (ATLL) was observed in northeast Italy, presenting with fever, lymphadenomegaly, splenomegaly, hypercalcemia and renal failure. Leukaemic cells were morphologically typical, expressed a T-cell CD4+ phenotype, did not display any helper functions, and grew in vitro under s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Fanin R,Minutillo S,D'Agaro P,Raspadori D,Tassinari A,Tazzari P,Testoni N,Damiani D,Gallizia C,Michieli M

    更新日期:1990-07-01 00:00:00

  • Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

    abstract::High-dose melphalan chemotherapy and autologous peripheral blood stem cell transplantation has been shown to result in durable hematologic response and prolonged overall survival in systemic AL amyloidosis. In this retrospective study, we evaluated clinical and hematologic responses in 69 patients with predominant liv...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2008.001925

    authors: Girnius S,Seldin DC,Skinner M,Finn KT,Quillen K,Doros G,Sanchorawala V

    更新日期:2009-07-01 00:00:00

  • Epidemiology of inhibitors and current treatment strategies.

    abstract::The development of inhibitors is currently one of the most serious complications in the treatment of hemophilic children. Prospective studies of previously untreated patients (PUP) showed that up to 52% of patients with severe hemophilia A developed inhibitors during the first 50 exposure days (ED) (>100 for outliers)...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Kreuz W,Ettingshausen CE,Auerswald G,Saguer IM,Becker S,Funk M,Heller C,Klarmann D,Klingebiel T,GTH PUP Study Group.

    更新日期:2003-06-01 00:00:00

  • Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

    abstract::The immunomodulatory drugs, lenalidomide and pomalidomide yield high response rates in multiple myeloma patients, but are associated with a high rate of thrombocytopenia and increased risk of secondary hematologic malignancies. Here, we demonstrate that the immunomodulatory drugs induce self-renewal of hematopoietic p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.188227

    authors: Liu A,Li S,Donnenberg V,Fu J,Gollin SM,Ma H,Lu C,Stolz DB,Mapara MY,Monaghan SA,Lentzsch S

    更新日期:2018-10-01 00:00:00

  • Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes.

    abstract:BACKGROUND:In normal platelets, insulin inhibits agonist-induced Ca(2+) mobilization by raising cyclic AMP. Platelet from patients with type 2 diabetes are resistant to insulin and show increased Ca(2+) mobilization, aggregation and procoagulant activity. We searched for the cause of this insulin resistance. DESIGN AN...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.054916

    authors: Gerrits AJ,Gitz E,Koekman CA,Visseren FL,van Haeften TW,Akkerman JW

    更新日期:2012-08-01 00:00:00

  • The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

    abstract::Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). However, whether these thrombophilic abnormalities are also risk factors for recurrent VTE is unclear. We conducted a systematic review of p...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.10234

    authors: Marchiori A,Mosena L,Prins MH,Prandoni P

    更新日期:2007-08-01 00:00:00

  • Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron.

    abstract::The transferability of the T2* technique for measurement of tissue iron between magnetic resonance (MR) scanners is unknown. Heart and liver multi-breath-hold T2* sequences were installed on MR scanners at six different sites. T2* was assessed locally in five or more patients with thalassemia major (n=39), and subject...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Tanner MA,He T,Westwood MA,Firmin DN,Pennell DJ,Thalassemia International Federation Heart T2* Investigators.

    更新日期:2006-10-01 00:00:00

  • Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

    abstract:BACKGROUND:Paroxysmal nocturnal hemoglobinuria (PNH) is associated with an increased risk of thrombosis through unknown mechanisms. DESIGN AND METHODS:We studied 23 patients with PNH, before and after five and 11 weeks of treatment with eculizumab. We examined markers of thrombin generation and reactional fibrinolysis...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2009.016121

    authors: Helley D,de Latour RP,Porcher R,Rodrigues CA,Galy-Fauroux I,Matheron J,Duval A,Schved JF,Fischer AM,Socié G,French Society of Hematology.

    更新日期:2010-04-01 00:00:00

  • Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio.

    abstract::In order to overcome the problem of different control genes for BCR-ABL normalization, we used a linear regression equation to compare our results previously obtained using B2M as the control gene with those calculated using the ABL gene and validated the slope as a factor to convert from B2M to ABL results. ...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.10632

    authors: Iacobucci I,Galletti L,Amabile M,Soverini S,Baccarani M,Martinelli G

    更新日期:2007-03-01 00:00:00

  • Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance.

    abstract:BACKGROUND:Assays to evaluate platelet function are often interchangeably used to assess "resistance" to aspirin. We compared different platelet function assays in patients treated or untreated with aspirin. DESIGN AND METHODS:Platelet function was evaluated in 162 subjects, 85 of whom were not being treated with any ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.027102

    authors: Renda G,Zurro M,Malatesta G,Ruggieri B,De Caterina R

    更新日期:2010-12-01 00:00:00

  • Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

    abstract::This phase Ib/II trial combined the pan-deacetylase inhibitor panobinostat with chemotherapy followed by panobinostat maintenance in elderly patients with newly diagnosed acute myeloid leukemia. Patients with prior history of myelodysplastic syndrome were excluded and 38 evaluable patients were included in the study (...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2015.129577

    authors: Ocio EM,Herrera P,Olave MT,Castro N,Pérez-Simón JA,Brunet S,Oriol A,Mateo M,Sanz MÁ,López J,Montesinos P,Chillón MC,Prieto-Conde MI,Díez-Campelo M,González M,Vidriales MB,Mateos MV,San Miguel JF,PETHEMA Group.

    更新日期:2015-10-01 00:00:00

  • Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.

    abstract::Krüppel-like factor 4 is a transcription factor with anti-proliferative effects in differentiated cells, but with the ability to reprogram adult cells into cell-cycling pluripotent cells. In cancer, Krüppel-like factor 4 acts as either an anti-oncogene or an oncogene. We analyzed Krüppel-like factor 4 gene expression ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.066944

    authors: Schoenhals M,Kassambara A,Veyrune JL,Moreaux J,Goldschmidt H,Hose D,Klein B

    更新日期:2013-09-01 00:00:00

  • Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.

    abstract:BACKGROUND AND OBJECTIVE:Idarubicin (IDA) is relatively immune to the multidrug resistance P-gp mechanism that is frequently expressed in recurrent and refractory hematologic malignancies. Owing to rapid metabolism in vivo, a continuous infusion (CI) of IDA might prolong exposure time to the parent drug rather than its...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bassan R,Chiodini B,Zucchetti M,Lerede T,Cornelli PE,Cortelazzo S,Barbui T

    更新日期:1998-01-01 00:00:00

  • CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.

    abstract::CLLU1, located at chromosome 12q22, encodes a transcript specific to chronic lymphocytic leukemia and has potential prognostic value. We assessed the value of CLLU1 expression in the LRF CLL4 randomized trial. Samples from 515 patients with chronic lymphocytic leukemia were collected immediately before the start of tr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.070201

    authors: Gonzalez D,Else M,Wren D,Usai M,Buhl AM,Parker A,Oscier D,Morgan G,Catovsky D

    更新日期:2013-02-01 00:00:00

  • Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

    abstract::Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic potential of ARV 825 ag...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.201483

    authors: Lim SL,Damnernsawad A,Shyamsunder P,Chng WJ,Han BC,Xu L,Pan J,Pravin DP,Alkan S,Tyner JW,Koeffler HP

    更新日期:2019-06-01 00:00:00

  • Autoimmune hemolytic anemia in multicentric Castleman's disease.

    abstract::We report on a patient affected by multicentric Castleman's disease who developed an acute immunohemolytic anemia due to warm antibody. The clinical course was characterized by refractoriness to the steroidal treatment and by a dramatic improvement of the hematological and objective picture following combination chemo...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Liberato NL,Bollati P,Chiofalo F,Filipponi M,Poli M

    更新日期:1996-01-01 00:00:00

  • Cell cycle kinetic changes induced by interleukin-3 and interleukin-6 during ex vivo expansion of mobilized peripheral blood CD34 cells.

    abstract::The long-term repopulating capacity of mobilized peripheral blood (MPB) CD34+ cells can be abrogated during ex vivo expansion due to cell-cycle related changes. In this study, we traced cell cycle kinetic and quiescent status of CD34+ cells during ex vivo expansion with exogenous cytokines. The addition of interleukin...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Sanchez-Garcia J,Torres A,Herrera C,Alvarez MA

    更新日期:2006-01-01 00:00:00

  • Fibrinogen survival and fibrinopeptide A in acute leukemia.

    abstract::BACKGROUND. Hypofibrinogenemia and increased fibrin(ogen) degradation products in acute leukemia have been attributed to intravascular thrombin generation triggered by leukemic cells. However, the strict relationship between fibrinogen catabolism and turnover of fibrinopeptide A (FPA), which is a sensitive and specifi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Castaman G,Galloni E,Dri AV,Rodeghiero F

    更新日期:1993-11-01 00:00:00

  • Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.

    abstract::New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of cell death by both se...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2017.185975

    authors: Matheson EC,Thomas H,Case M,Blair H,Jackson RK,Masic D,Veal G,Halsey C,Newell DR,Vormoor J,Irving JAE

    更新日期:2019-09-01 00:00:00

  • Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

    abstract:BACKGROUND AND OBJECTIVES:The detection of PML-RARalpha by real-time polymerase chain reaction (RQ-PCR) is becoming an important tool for monitoring minimal residual disease (MRD) in patients with acute promyelocytic leukemia (APL). However, its clinical value remains to be determined. Our aim was to analyze any associ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.10734

    authors: Santamaría C,Chillón MC,Fernández C,Martín-Jiménez P,Balanzategui A,García Sanz R,San Miguel JF,González MG

    更新日期:2007-03-01 00:00:00

  • Role of hepatocyte growth factor in the development of dendritic cells from CD34+ bone marrow cells.

    abstract:BACKGROUND AND OBJECTIVE:Hepatocyte growth factor (HGF) is known to augment the effects of stem cell factor, interleukin-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoetin, and granulocyte colony-stimulating factor, all of which are involved in hematopoiesis. HGF is also known to have a role in...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Ovali E,Ratip S,Kibaroglu A,Tekelioglu Y,Cetiner M,Karti S,Aydin F,Bayik M,Akoglu T

    更新日期:2000-05-01 00:00:00

  • Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

    abstract::Evaluation of Anagrelide (Xagrid®) Efficacy and Long-term Safety, a phase IV, prospective, non-interventional study performed in 13 European countries enrolled high-risk essential thrombocythemia patients treated with cytoreductive therapy. The primary objectives were safety and pregnancy outcomes. Of 3721 registered ...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2017.174672

    authors: Birgegård G,Besses C,Griesshammer M,Gugliotta L,Harrison CN,Hamdani M,Wu J,Achenbach H,Kiladjian JJ

    更新日期:2018-01-01 00:00:00